Sichuan Biokin Pharmaceutical (SHA:688506) returned to its special account the 700 million yuan that was used to temporarily supplement its working capital, according to a Shanghai bourse filing on Thursday.
The amount was previously idle funds that were used to fund working capital, especially for drug research and development.